This course focuses on antimicrobial stewardship as an approach to address healthcare-associated infections (HAI) resulting from multi-drug resistance organisms in acute care settings.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.
The main aim of the genomic study described in this surveillance report was to determine the distribution of the highly drug-resistant clade of Klebsiella pneumoniae (sequence type (ST) 39 in Greek hospitals in 2022.